Study:
Phase II Trial of Sorafenib in Conjunction With Chemotherapy and as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Rationale:
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving sorafenib together
with combination chemotherapy may kill more tumor cells.
Purpose:
This phase II trial is studying how well giving sorafenib together with cisplatin
and etoposide works in treating patients with extensive-stage small cell lung cancer.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lung Cancer |
Drug: cisplatin
Drug: etoposide
Drug: sorafenib tosylate |
Phase 2 |
Verified by
Afshin Dowlati, MD
February, 2013
Sponsored by: Afshin Dowlati, MD
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00726986
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Afshin Dowlati, MD., Principal Investigator
Nathan Pennell, MD., Principal Investigator